Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ammoxetine in Subjects With Depression
NCT06827431Phase 3Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Feb 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ammoxetine in major depressive disorder (MDD) (4 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Feb 2025; status: completed.
02
Drugs
ammoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06827431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827431.